8CC Stock Financial Analysis - Cocrystal Pharma, Inc. (DB) Stock

Overview

Cocrystal Pharma, Inc., based in the United States, operates in the biotechnology sector with a focus on discovering and developing novel antiviral therapeutics. The company leverages proprietary technology to design unique treatments targeting viral replication enzymes, addressing diseases such as influenza, coronavirus, and norovirus. As of 2023, Cocrystal Pharma has been actively developing broad-spectrum antiviral drugs, including candidates for COVID-19 and influenza. Key projects include the preclinical development of CC-42344, a potent influenza A polymerase inhibitor, and ongoing work on inhibitors targeting the replication machinery of coronaviruses, underscoring its commitment to addressing global antiviral drug resistance challenges through innovative pharmaceutical developments.

Quality, Value, Momentum Scores

This card shows the Quality, Value, and Momentum scores for the company

Quality

The QualityScore is a proprietary scoring model that identifies high quality companies, based on cash generating efficiencies.

Value

Proprietary scoring model that ranks companies based on their relative valuation. Scores range from 0 to 100, with 100 being the most undervalued.

Momentum

Proprietary scoring model that ranks companies on their six-month momentum.

Fund Sentiment

The Fund Sentiment (fka Ownership) score is a proprietary quantitative model that ranks companies based on levels of ownership accumulation.

QVM

The QVM Score is a proprietary scoring model that combines Quality, Value, and Momentum into a single metric that ranks companies from 0 to 100.

Income Statement: Revenue, Operating Income, Net Income

The operating income for Cocrystal Pharma, Inc. as of 30 June 2025 is -12.72 MM.
The net income for Cocrystal Pharma, Inc. as of 30 June 2025 is -12.56 MM.

Period End (TTM)	Revenue (MM)	Operating Income (MM)	Net Income (MM)
2025-06-30		-12.72	-12.56
2025-03-31		-16.06	-15.85
2024-12-31		-17.88	-17.50
2024-09-30		-20.31	-18.70
2024-06-30		-21.32	-17.93
2024-03-31		-20.21	-16.75
2023-12-31		-21.16	-17.98
2023-09-30		-20.00	-18.02
2023-06-30		-19.65	-19.56
2023-03-31		-19.04	-39.82
2022-12-31		-18.14	-38.84
2022-09-30		-17.34	-38.02
2022-06-30		-15.60	-36.26
2022-03-31		-15.69	-15.65
2021-12-31		-14.22	-14.19
2021-09-30	0.51	-11.98	-11.99
2021-06-30	1.00	-10.74	-10.72
2021-03-31	1.55	-10.36	-10.40
2020-12-31	2.01	-9.59	-9.65
2020-09-30	1.91	-9.94	-56.00
2020-06-30
2020-03-31

Income Statement: EPS

Period End (TTM)	Earnings Per Share Basic	Earnings Per Share Diluted
2025-06-30
2025-03-31
2024-12-31
2024-09-30	-1.84	-1.84
2024-06-30	-1.76	-1.76
2024-03-31	-1.65	-1.65
2023-12-31	-1.86
2023-09-30	-1.97	-1.97
2023-06-30	-2.27	-2.27
2023-03-31	-4.89	-4.89
2022-12-31	-4.77
2022-09-30	-4.67	-4.67
2022-06-30	-4.46	-4.46
2022-03-31	-1.98	-1.98
2021-12-31	-1.93
2021-09-30	-1.77	-1.77
2021-06-30	-1.80	-1.80
2021-03-31	-1.99	-1.99
2020-12-31	-2.10
2020-09-30	-14.51	-14.51
2020-06-30	-16.60	-16.63
2020-03-31	-18.38	-18.40

Cash Flow: Operations, Investing, Financing

The cash from operating activities for Cocrystal Pharma, Inc. as of 30 June 2025 is -13.38 MM.
The cash from investing activities for Cocrystal Pharma, Inc. as of 30 June 2025 is 0.00 MM.

Period End (TTM)	Cash From Operating Activities (MM)	Cash From Investing Activities (MM)	Cash From Financing Activities (MM)
2025-06-30	-13.38	0.00
2025-03-31	-14.92	0.00
2024-12-31	-16.48	-0.01
2024-09-30	-16.65	-0.07	0.00
2024-06-30	-14.21	-0.07	0.00
2024-03-31	-16.06	-0.08	4.00
2023-12-31	-14.67	-0.12	3.99
2023-09-30	-16.23	-0.07	3.99
2023-06-30	-22.46	-0.13	3.98
2023-03-31	-20.64	-0.12	-0.03
2022-12-31	-21.43	-0.07	-0.03
2022-09-30	-19.46	-0.07	-0.03
2022-06-30	-15.96	-0.01	-0.03
2022-03-31	-14.86	-0.03	36.40
2021-12-31	-12.72	-0.05	38.47
2021-09-30	-12.18	-0.04	42.09
2021-06-30	-9.84	-0.06	57.64
2021-03-31	-9.41	-0.17	21.18
2020-12-31	-9.83	-0.24	35.66
2020-09-30	-8.68	-0.24	34.71
2020-06-30
2020-03-31

Valuation Metrics : PE, PriceToBook, PriceToTBV

P/Book: The current closing price divided by the book value per share.

P/TBV: The current price divided by the tangible book value per share.

Period End (TTM)	p/e	P/Book	P/TBV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31

Valuation Metrics : EBitToEv, EBit3YrAvgToEv

Period End (TTM)	EBIT/EV	EBIT (3y)/EV
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31

Management Effectiveness

The roa for Cocrystal Pharma, Inc. as of 30 June 2025 is -0.73.
The roe for Cocrystal Pharma, Inc. as of 30 June 2025 is -0.72.
The roic for Cocrystal Pharma, Inc. as of 30 June 2025 is -1.75.
The croic for Cocrystal Pharma, Inc. as of 30 June 2025 is -1.65.
The ocroic for Cocrystal Pharma, Inc. as of 30 June 2025 is -1.65.

Period End (TTM)	ROA	ROE	ROIC	CROIC	OCROIC
2025-06-30	-0.73	-0.72	-1.75	-1.65	-1.65
2025-03-31	-0.70	-0.70	-1.28	-1.15	-1.14
2024-12-31	-0.60	-0.66	-1.28	-1.15	-1.14
2024-09-30	-0.57	-0.61	-0.94	-0.74	-0.74
2024-06-30	-0.44	-0.48	-0.69	-0.50	-0.66
2024-03-31	-0.44	-0.45	-0.58	-0.40	-0.53
2023-12-31			-0.58	-0.40	-0.53
2023-09-30	-0.37	-0.40	-0.56	-0.53	-0.64
2023-06-30	-0.76	-0.40	-0.56	-0.53	-0.64
2023-03-31		-0.54	-1.14	-0.60
2022-12-31		0.00
2022-09-30	-0.46	-0.47	-0.86	-0.44	-0.44
2022-06-30	-0.41	-0.43	-0.73	-0.32	-0.32
2022-03-31	-0.29	-0.30	-0.21	0.29	-0.20
2021-12-31	-0.26	-0.27	-0.18	0.33	-0.16
2021-09-30	-0.23	-0.24	-0.15	0.37	-0.15
2021-06-30	-0.26	-0.29	-0.13	0.56	-0.12
2021-03-31	-0.24	-0.26	-0.20	0.22	-0.18
2020-12-31	-0.34	-0.38	-0.18	0.48	-0.19
2020-09-30	-0.76	-0.79	-1.10	0.51	-0.17
2020-06-30	-0.74	-0.76	-1.46	0.31	-0.18
2020-03-31	-0.70	-0.72	-1.29	0.32	-0.14

Gross Margins

Gross Margin: The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.

Net Margin: The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.

Operating Margin: The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.

Period End (TTM)	Gross Margin	Net Margin	Operating Margin
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31	-18.78	-30.70	-30.76
2021-12-31	-16.24	-27.81	-27.88
2021-09-30	-13.63	-23.52	-23.50
2021-06-30	-6.38	-10.73	-10.75
2021-03-31	-3.07	-6.69	-6.67
2020-12-31	-2.13	-4.79	-4.76
2020-09-30	-2.30	-29.38	-5.22
2020-06-30	-1.77	-28.87	-4.74
2020-03-31	-1.26	-27.29	-3.67